Skip to main content
OrthoVellum
Knowledge Hub

Study

  • Topics
  • MCQs
  • ISAWE
  • Operative Surgery
  • Flashcards

Company

  • About Us
  • Editorial Policy
  • Contact
  • FAQ
  • Blog

Legal

  • Terms of Service
  • Privacy Policy
  • Cookie Policy
  • Medical Disclaimer
  • Copyright & DMCA
  • Refund Policy

Support

  • Help Center
  • Accessibility
  • Report an Issue
OrthoVellum

Ā© 2026 OrthoVellum. For educational purposes only.

Not affiliated with the Royal Australasian College of Surgeons.

Oncology
intermediate
X-Type

Denosumab in Bone Tumors

Medical Management

A 28-year-old woman has a giant cell tumor (GCT) of the distal radius extending to the subchondral bone with soft tissue extension. En bloc resection would require wrist arthrodesis. The multidisciplinary tumor board discusses the role of neoadjuvant denosumab to potentially allow joint-preserving surgery. Regarding denosumab in bone tumors:

Mark each as TRUE or FALSE

A

Denosumab is a fully human monoclonal antibody that binds RANKL (Receptor Activator of Nuclear Facto...

B

In giant cell tumor, the neoplastic stromal cells express RANKL, recruiting and activating osteoclas...

C

Denosumab directly kills the neoplastic cells in GCT; it is a bisphosphonate; RANKL inhibition incre...

D

Side effects include hypocalcemia (calcium and vitamin D supplementation required), osteonecrosis of...

E

In metastatic bone disease, denosumab reduces skeletal-related events (pathological fractures, spina...

Answer the questions to see explanations

Click T (True) or F (False) for each option